106 related articles for article (PubMed ID: 36211243)
1. Case for investment in tobacco cessation: a population-based analysis in low- and middle-income countries.
Sandoval GA; Totanes R; David AM; Fu D; Bettcher D; Prasad V; Arnold V
Rev Panam Salud Publica; 2022; 46():e71. PubMed ID: 36211243
[TBL] [Abstract][Full Text] [Related]
2. Building the foundations for sustainable development: a case for global investment in the capabilities of adolescents.
Sheehan P; Sweeny K; Rasmussen B; Wils A; Friedman HS; Mahon J; Patton GC; Sawyer SM; Howard E; Symons J; Stenberg K; Chalasani S; Maharaj N; Reavley N; Shi H; Fridman M; Welsh A; Nsofor E; Laski L
Lancet; 2017 Oct; 390(10104):1792-1806. PubMed ID: 28433259
[TBL] [Abstract][Full Text] [Related]
3. Saving newborn lives in Asia and Africa: cost and impact of phased scale-up of interventions within the continuum of care.
Darmstadt GL; Walker N; Lawn JE; Bhutta ZA; Haws RA; Cousens S
Health Policy Plan; 2008 Mar; 23(2):101-17. PubMed ID: 18267961
[TBL] [Abstract][Full Text] [Related]
4. The return on investment of a Medicaid tobacco cessation program in Massachusetts.
Richard P; West K; Ku L
PLoS One; 2012; 7(1):e29665. PubMed ID: 22238633
[TBL] [Abstract][Full Text] [Related]
5. Guide posts for investment in primary health care and projected resource needs in 67 low-income and middle-income countries: a modelling study.
Stenberg K; Hanssen O; Bertram M; Brindley C; Meshreky A; Barkley S; Tan-Torres Edejer T
Lancet Glob Health; 2019 Nov; 7(11):e1500-e1510. PubMed ID: 31564629
[TBL] [Abstract][Full Text] [Related]
6. Investment case for small and sick newborn care in Tanzania: systematic analyses.
Kamuyu R; Tarus A; Bundala F; Msemo G; Shamba D; Paul C; Tillya R; Murless-Collins S; Oden M; Richards-Kortum R; Powell-Jackson T; Kumar MB; Salim N; Lawn JE
BMC Pediatr; 2023 Dec; 23(Suppl 2):632. PubMed ID: 38098013
[TBL] [Abstract][Full Text] [Related]
7. The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment.
O'Donnell MP; Roizen MF
Am J Health Promot; 2011; 26(1):e11-23. PubMed ID: 21879928
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
Cromwell J; Bartosch WJ; Fiore MC; Hasselblad V; Baker T
JAMA; 1997 Dec; 278(21):1759-66. PubMed ID: 9388153
[TBL] [Abstract][Full Text] [Related]
9. Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries.
Schäferhoff M; Zimmerman A; Diab MM; Mao W; Chowdhary V; Gill D; Karanja R; Madikizela M; Ogbuoji O; Yamey G
Lancet Glob Health; 2022 Jul; 10(7):e1045-e1052. PubMed ID: 35714631
[TBL] [Abstract][Full Text] [Related]
10. Unassisted Quitting and Smoking Cessation Methods Used in the United States: Analyses of 2010-2011 Tobacco Use Supplement to the Current Population Survey Data.
Soulakova JN; Crockett LJ
Nicotine Tob Res; 2017 Dec; 20(1):30-39. PubMed ID: 27798084
[TBL] [Abstract][Full Text] [Related]
11. Global return on investment and cost-effectiveness of WHO's HEAR interventions for hearing loss: a modelling study.
Tordrup D; Smith R; Kamenov K; Bertram MY; Green N; Chadha S;
Lancet Glob Health; 2022 Jan; 10(1):e52-e62. PubMed ID: 34919856
[TBL] [Abstract][Full Text] [Related]
12. A Health System-Based Investment Case for Adolescent Health.
Sweeny K; Friedman HS; Sheehan P; Fridman M; Shi H
J Adolesc Health; 2019 Jul; 65(1S):S8-S15. PubMed ID: 31228990
[TBL] [Abstract][Full Text] [Related]
13. Tobacco cessation interventions for young people.
Grimshaw GM; Stanton A
Cochrane Database Syst Rev; 2006 Oct; (4):CD003289. PubMed ID: 17054164
[TBL] [Abstract][Full Text] [Related]
14. One world, one hope: the cost of providing antiretroviral therapy to all nations.
Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
[TBL] [Abstract][Full Text] [Related]
15. A cost-benefit analysis of smoking cessation prescription coverage from a US payer perspective.
Baker CL; Ding Y; Ferrufino CP; Kowal S; Tan J; Subedi P
Clinicoecon Outcomes Res; 2018; 10():359-370. PubMed ID: 30038510
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
17. Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.
Rodin D; Burger EA; Atun R; Barton M; Gospodarowicz M; Grover S; Hanna TP; Jaffray DA; Knaul FM; Lievens Y; Zubizarreta E; Milosevic M
Lancet Oncol; 2019 Jul; 20(7):915-923. PubMed ID: 31151906
[TBL] [Abstract][Full Text] [Related]
18. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles.
Gilbert AR; Pinget C; Bovet P; Cornuz J; Shamlaye C; Paccaud F
Tob Control; 2004 Jun; 13(2):190-5. PubMed ID: 15175539
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
